Inotrem raises €39M series B for septic shock therapy, diagnostic

A €39 million ($43 million) series B round raised by Inotrem will allow the French biotech to get its lead program for septic shock through Phase IIb testing.

Morningside

Read the full 286 word article

User Sign In